Fulminant Guillain Barre syndrome with recurrent lung collapse


  • Hasif Kolleri Department of Clinical Pharmacology, Apollo Children Hospital, Chennai, Tamil Nadu, India
  • Mohammed Fardan Department of Clinical Pharmacology, Apollo Children Hospital, Chennai, Tamil Nadu, India
  • A. Priya Department of Clinical Pharmacology, Apollo Children Hospital, Chennai, Tamil Nadu, India




Polyneuropathy, Flaccid weakness, Respiratory failure


Fulminant Guillain-Barré syndrome (GBS) is a rapidly progressive form of polyneuropathy in which patients demonstrate eventual flaccid quadriplegia and an absence of brainstem function. Most patients present initially with a mild upper respiratory or gastrointestinal illness and have non-diagnostic cerebral imaging studies. Here we report the case of child aged 7 who was admitted initially with complaints of weakness of lower limbs lasting for 4-5 hours. He had difficulty in standing and walking, associated with pain in both lower limbs. Flaccid weakness rapidly progressed over 12 hours to involve both upper limbs along with difficulty in swallowing and nasal regurgitation of feeds. He was intubated and mechanically ventilated for respiratory failure. Over the period of time, after confirmation with all the test reports and symptoms, other differential diagnoses were ruled out and fulminant GBS was considered and hence plasmapheresis was started. Over the period of 3 months his muscle power slowly improved. During discharge, he was able to lift limbs against minimal resistance, turn sideways on bed, sit up with minimal support and likewise stand with support.


Chung A, Deimling M. Guillain-Barre Syndrome. Pediatrics in Review. 2018;39(1):53-4.

Kraft GH, Freal JE, Coryell JK. Disability, disease duration and rehabilitation service needs in multiple sclerosis: patient perspectives. Arch Phys Med Rehabil. 1986;67(3):164-8.

Hughes RAC , Swan AV, Raphaël JC, Annane D, Koningsveld, Doorn PA, et al. Immunotherapy for Guillain Barre Syndrome: a systemic review. Brain. 2007;130:2245-57.

Hugesh RA, Swan AV, Van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2014(9):CD002063.

Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain Barre Syndrome. Cochrane Database Syst Rev. 2012;11(7):CD001798.

Hund EF, Borel CO, Cornblath DR, Hanley DF, McKhann GM. Intensive management and treatment of severe Guillain-Barre syndrome. Crit. Care Med. 1993;21:433-46.

Ormerod IE, Ceekerell OC. Guillain-Barre syndrome after herpes zoster infection: a report of 2 cases. Eur Neurol. 1993;33(2):156-8.

Miller RG. Guillain Barre syndrome. Postgraduate Medicine. 1985;77(7):57-64.

Murray DP. Impaired mobility: Guillain-Barre syndrome. J Neurosci Nurs. 1993;25(2):100-4.

Hughes RAC , Wijdicks EFM, Benson E, Cornblath DR, Hahn AF, Meythaler JM, et al. Supportive care for patients with Guillain-Barre syndrome. Arch Neurol. 2005;62(8):1194-8.

Van Doorn P.A, Ruts L, Jacobs B.C. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. The Lancet. Neurology 2008;7(10):939-50.




How to Cite

Kolleri, H., Fardan, M., Priya, A., & Chander, K. A. (2020). Fulminant Guillain Barre syndrome with recurrent lung collapse. International Journal of Basic & Clinical Pharmacology, 10(1), 127–129. https://doi.org/10.18203/2319-2003.ijbcp20205551



Case Reports